COMMUNIQUÉS West-GlobeNewswire

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
28/01/2026
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]
Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals
28/01/2026
Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United States Patent and [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
28/01/2026
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE [...]
HealthEdge® and Suki Introduce Ambient Clinical Intelligence for Care Management
28/01/2026
Integration of Suki with HealthEdge GuidingCare® Delivers AI-Powered Automation That Reduces Administrative Burden for Care Managers and Elevates Care Quality BOSTON and REDWOOD CITY, Calif., Jan. 28, 2026 (GLOBE [...]
Cannara annonce l'approbation conditionnelle de sa migration vers la Bourse de Toronto
28/01/2026
MONTRÉAL, 28 janv. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Bexorg Awarded Grant from The Michael J. Fox Foundation to Identify Translational Biomarkers for TRPML1-Targeted Parkinson’s Disease Therapies
28/01/2026
- TRPML1 is a promising target 1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies - Bexorg will leverage its postmortem whole-human [...]
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
28/01/2026
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this [...]
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
28/01/2026
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Wandercraft Appoints Permobil CEO Chuck Witkowski to Board of Directors, Signaling a New Phase of Growth and Global Commercialization
28/01/2026
PARIS and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Wandercraft, a pioneer in the development of self-balancing robotics, today announced the appointment of Chuck Witkowski, CEO of Permobil, to its Board of Directors [...]
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
28/01/2026
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the formal commencement [...]
NetraMark Closes First Tranche of Private Placement
28/01/2026
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
Medline to report fourth quarter and full year 2025 results on February 25, 2026
28/01/2026
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A [...]
Altanine Appoints Patrice Launay as Chief Financial Officer
28/01/2026
Seasoned public company finance executive brings deep expertise in SEC reporting, capital markets, and scaling high-growth companies LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Altanine , a specialty pharmaceutical [...]
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
28/01/2026
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees [...]
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
28/01/2026
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
28/01/2026
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the [...]
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
28/01/2026
Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships and market expansion Woodland, CA, Jan. 28, 2026 (GLOBE [...]
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
28/01/2026
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB [...]

Pages